KDM1A and acute myeloid leukemia: In AML, therapeutic resistance can arise in the apparent absence of new genetic mutations and is antagonized by inhibiting Lsd1, a demethylase chromatin modulator involved in the regulation of enhancer activity.219 Inhibition of Lsd1 creates enhancer switching, generating new binding sites for pioneer factors that ultimately activate the enhancers of key drug resistance genes.